Approved comparison material connected to this topic.
3 total recordsSource comparisons are presented without a generated winner.
HIV lipodystrophy (protease inhibitor regimen) 180–220 cm² 18–22% (32–48 cm² loss) −4.2 to −5.1 cm Protease inhibitors suppress endogenous GH; tesamorelin restores pulsatility more effectively in this group HI…
| Intervention | Mean VAT Reduction (26 weeks) | Subcutaneous Fat Impact | Lean Mass Change | Durability After Discontinuation | Primary Mechanism | Professional Assessment ||—|—|—|—|—|—|| Tesamorelin 2mg dail…
Daily Dose 2mg subcutaneous once daily 2–4 IU subcutaneous daily (lipodystrophy context) N/A Tesamorelin preserves endogenous pulsatility; exogenous GH suppresses natural secretion Administration Timing Fastin…